Feds seek drug data from Scios

Federal prosecutors in Massachusetts have subpoenaed Johnson & Johnson subsidiary Scios for documents related to the sale of Natrecor, its drug for congestive heart failure. Some critics contend that Natrecor increases the risk of kidney problems and even death in some patients. Researchers reported in a small study April 20 that they found evidence that patients given Natrecor appeared much more likely to die in the first month after treatment than those given traditional medication, such as nitroglycerin. Scios is performing additional tests on the drug and plans to notify doctors not to use Natrecor off-label.

- read this report from the San Jose Mercury News for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.